Pan-drug resistant Providencia rettgeri contributing to a fatal case of COVID-19

References

1. Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect Dis 2020; 20:533–534 [View Article] [PubMed]
   [Google Scholar]
2. Sommer DD, Engels PT, Weitzel EK, Khalili S, Corsten M. Recommendations from the CSO-HNS taskforce on performance of tracheotomy during the COVID-19 pandemic. J Otolaryngol Head Neck Surg 2020; 49:23 [View Article] [PubMed]
   [Google Scholar]
3. Schmidt M, Hajage D, Lebreton G, Monsel A, Voiriot G. Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome associated with COVID-19: a retrospective cohort study. Lancet Respir Med 2020; 8:1121–1131 [View Article] [PubMed]
   [Google Scholar]
4. Boev C, Kiss E. Hospital-acquired infections: Current trends and prevention. Crit Care Nurs Clin North Am 2017; 29:51–65 [View Article] [PubMed]
   [Google Scholar]
5. Contou D, Claudinon A, Pajot O, Micaelo M, Longuet Flandre P. Bacterial and viral co-infections in patients with severe SARS-CoV-2 pneumonia admitted to a French ICU. Ann Intensive Care 2020; 10:119 [View Article] [PubMed]
   [Google Scholar]
6. Garcia-Vidal C, Sanjuan G, Moreno-García E, Puerta-Alcalde P, Garcia-Pouton N et al. Incidence of co-infections and superinfections in hospitalized patients with COVID-19: A retrospective cohort study. Clin Microbiol Infect 2020; 27:83–88 [View Article]
   [Google Scholar]
7. Rawson TM, Moore LSP, Zhu N, Ranganathan N, Skolimowska K et al. Bacterial and fungal coinfection in individuals with coronavirus: A rapid review to support COVID-19 antimicrobial prescribing. Clin Infect Dis 2020; 71:2459–2468 [View Article] [PubMed]
   [Google Scholar]
8. Bauer KA, Kullar R, Gilchrist M, File TM Jr. Antibiotics and adverse events: the role of antimicrobial stewardship programs in “doing no harm”. Curr Opin Infect Dis 2019; 32:553–558 [View Article]
   [Google Scholar]
9. Emeraud C, Escaut L, Boucly A, Fortineau N, Bonnin RA et al. Aztreonam plus Clavulanate, Tazobactam, or Avibactam for treatment of infections caused by Metallo-beta-Lactamase-producing Gram-negative bacteria. Antimicrob Agents Chemother 2019; 63: [View Article] [PubMed]
   [Google Scholar]
10. Sader HS, Carvalhaes CG, Arends SJR, Castanheira M, Mendes RE. Aztreonam/avibactam activity against clinical isolates of Enterobacterales collected in Europe, Asia and Latin America in 2019. J Antimicrob Chemother 2020
    [Google Scholar]
11. Galac MR, Snesrud E, Lebreton F, Stam J, Julius M et al. A diverse panel of clinical Acinetobacter baumannii for research and development; 2020; 64
12. Ito A, Sato T, Ota M, Takemura M, Nishikawa T et al. In vitro antibacterial properties of cefiderocol, a novel siderophore sephalosporin, against gram-negative bacteria. Antimicrob Agents Chemother 2018; 62: [View Article]
    [Google Scholar]
13. Kohira N, Hackel MA, Ishioka Y, Kuroiwa M, Sahm DF. Reduced susceptibility mechanism to cefiderocol, a siderophore cephalosporin, among clinical isolates from a global surveillance programme (SIDERO-WT-2014. J Glob Antimicrob Resist 2020; 22:738–741 [View Article] [PubMed]
    [Google Scholar]
14. Simner PJ, Patel R. Cefiderocol antimicrobial susceptibility testing considerations: the achilles heel of the trojan horse?. J Clin Microbiol 2020; 59: [View Article]
    [Google Scholar]
15. Livermore DM, Mushtaq S, Warner M, Woodford N. In vitro activity of eravacycline against Carbapenem-resistant Enterobacteriaceae and Acinetobacter baumannii. Antimicrob Agents Chemother 2016; 60:3840–3844 [View Article] [PubMed]
    [Google Scholar]
16. Morley VJ, Woods RJ, Read AF. Bystander selection for antimicrobial resistance: Implications for patient health. Trends Microbiol 2019; 27:864–877 [View Article] [PubMed]
    [Google Scholar]